Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens.

Abstract Background: Nonmelanoma skin cancer occurs frequently in organ transplant recipients, but the relative importance of different immunosuppressive therapy regimens is unclear. Objective: We studied the risk of skin cancer in the complete, single-center Norwegian cohort of kidney and heart transplant recipients (n = 2561). Methods: We determined cancer risk estimation by means of standardized incidence ratios and multivariate Cox regression. Results: Transplant recipients had an increased risk of cutaneous squamous cell carcinoma (SCC) (65-fold), malignant melanoma (3-fold), and Kaposi's sarcoma (84-fold), and of lip SCC (20-fold), compared with the general population. After adjustment for age, kidney transplant recipients receiving cyclosporine, azathioprine, and prednisolone had a significantly (2.8 times) higher risk of cutaneous SCC relative to those receiving azathioprine and prednisolone. After adjustment for age and type of immunosuppressive regimen, heart transplant recipients had a significantly (2.9 times) higher risk than kidney transplant recipients. Conclusion: The risk of cutaneous SCC, malignant melanoma, Kaposi's sarcoma, and lip SCC is increased in kidney and heart transplant recipients. The risk of posttransplant cutaneous SCC is related to the degree of immunosuppression caused by long-term immunosuppressive therapy. (J Am Acad Dermatol 1999;40:177-86.)

[1]  Jean Kanitakis,et al.  Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. , 1995, Journal of the American Academy of Dermatology.

[2]  J. Szepietowski,et al.  Excess benign melanocytic naevi in renal transplant recipients. , 1997, Dermatology.

[3]  F. Claas,et al.  Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. , 1997, The Journal of investigative dermatology.

[4]  Jean Kanitakis,et al.  Aggressive squamous cell carcinomas in organ transplant recipients. , 1995, Transplantation proceedings.

[5]  Norman E. Breslow,et al.  The design and analysis of cohort studies , 1987 .

[6]  J. McGregor,et al.  Excess melanocytic nevi in children with renal allografts. , 1993, Journal of the American Academy of Dermatology.

[7]  P. Rieu,et al.  Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. , 1997, Transplantation proceedings.

[8]  McGregor Jm,et al.  The role of papillomaviruses in human non-melanoma skin cancer. , 1996 .

[9]  Cunliffe,et al.  The compliance of renal transplant recipients with advice about sun protection measures , 1998, The British journal of dermatology.

[10]  W. Qunibi,et al.  Kaposi's sarcoma in renal transplant recipients: a report on 26 cases from a single institution. , 1993, Transplantation proceedings.

[11]  M. Kaplan,et al.  Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma , 1995, The Lancet.

[12]  E. Will,et al.  Risk of neoplasia in renal transplant patients , 1995, The Lancet.

[13]  E. Thorsby,et al.  Results of the National Kidney Transplantation Program in Norway. , 1992, Clinical transplants.

[14]  E. Abel.  Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients: King GN, Healy CM, Glover MT, et al. N Engl J Med 1995;332:1052–1057 , 1995 .

[15]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[16]  E. Abel.  Cutaneous manifestations of immunosuppression in organ transplant recipients. , 1989, Journal of the American Academy of Dermatology.

[17]  G. Nabel.  A transformed view of cyclosporine , 1999, Nature.

[18]  F. Langmark,et al.  Head and neck cancer in Norway , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  H. Worthington,et al.  Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. , 1995, The New England journal of medicine.

[20]  B. O'Sullivan,et al.  The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. , 1996, Transplantation.

[21]  A. Sheil,et al.  Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients , 1992 .

[22]  I. Penn,et al.  Cancers in cyclosporine-treated vs azathioprine-treated patients. , 1996, Transplantation proceedings.

[23]  J. Bodmer,et al.  HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. , 1993, European journal of cancer.

[24]  E. Benton,et al.  HUMAN PAPILLOMA VIRUS INFECTION AND SKIN CANCER IN RENAL ALLOGRAFT RECIPIENTS , 1989, The Lancet.

[25]  J. Vandenbroucke,et al.  Incidence of skin cancer after renal transplantation in The Netherlands. , 1990, Transplantation.

[26]  J. Herreros,et al.  Skin cancer in heart transplant recipients. , 1995, Journal of the American Academy of Dermatology.

[27]  N. E. Breslow.  Statistical Methods in Cancer Research , 1986 .

[28]  D. Czarnecki,et al.  Skin cancers and HLA frequencies in renal transplant recipients. , 1992, Dermatology.

[29]  Kengo Morimoto,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[30]  M. Kietzmann,et al.  Steroid-induced dermal thinning: discontinuous application of clobetasol-17-propionate ointment. , 1992, Dermatology.

[31]  O. Larkö,et al.  No difference in skin cancer incidence with or without cyclosporine--a 5-year perspective. , 1992, Transplantation proceedings.

[32]  O. Larkö,et al.  Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. , 1990, Acta dermato-venereologica.

[33]  Sheil Ag.  Skin cancer in renal transplant recipients. , 1994, Transplantation science.

[34]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[35]  G. Nanni,et al.  Kaposi's sarcoma in renal-transplant recipients: experience at the Catholic University in Rome, 1988-1996. , 1997, Dermatology.

[36]  J. Vandenbroucke,et al.  HLA-A11-associated resistance to skin cancer in renal-transplant recipients. , 1990, The New England journal of medicine.

[37]  D. Dyall-smith,et al.  Cutaneous malignancies in renal transplant recipients from Nova Scotia, Canada , 1995, The Australasian journal of dermatology.

[38]  S. Simonsen,et al.  Cutaneous complications in heart transplant recipients in Norway 1983-1993. , 1995, Acta dermato-venereologica.

[39]  C. Newstead.  Assessment of risk of cancer after renal transplantation , 1998, The Lancet.

[40]  J. Vandenbroucke,et al.  Relation between skin cancer and HLA antigens in renal-transplant recipients. , 1991, The New England journal of medicine.

[41]  E. Benton,et al.  The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  J. Salaman,et al.  Epidermal dysplasia and cyclosporine therapy in renal transplant patients: a comparison with azathioprine , 1989, The British journal of dermatology.

[43]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[44]  D. Dunn,et al.  De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. , 1994, Clinical transplantation.

[45]  D. Leffell,et al.  The molecular basis of nonmelanoma skin cancer: new understanding. , 1997, Archives of dermatology.

[46]  B. Dréno,et al.  Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens , 1998, The Lancet.

[47]  C. Raskin,et al.  Apoptosis and cutaneous biology. , 1997, Journal of the American Academy of Dermatology.

[48]  C. Proby,et al.  Skin cancer in transplant recipients , 1995, The Lancet.

[49]  M. Raftery,et al.  Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients , 1997, The Lancet.

[50]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[51]  J. McGregor,et al.  Posttransplant skin cancer: a possible role for p53 gene mutation but not for oncogenic human papillomaviruses. , 1994, Journal of the American Academy of Dermatology.